BRPI0814874A2 - combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer. - Google Patents

combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer.

Info

Publication number
BRPI0814874A2
BRPI0814874A2 BRPI0814874A BRPI0814874A BRPI0814874A2 BR PI0814874 A2 BRPI0814874 A2 BR PI0814874A2 BR PI0814874 A BRPI0814874 A BR PI0814874A BR PI0814874 A BRPI0814874 A BR PI0814874A BR PI0814874 A2 BRPI0814874 A2 BR PI0814874A2
Authority
BR
Brazil
Prior art keywords
combination
kinase inhibitor
aurora kinase
antimitotic agent
anticancer treatment
Prior art date
Application number
BRPI0814874A
Other languages
English (en)
Inventor
Dawn Basso-Porcaro Andrea
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40305124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814874(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0814874A2 publication Critical patent/BRPI0814874A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0814874A 2007-07-31 2008-07-28 combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer. BRPI0814874A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95308707P 2007-07-31 2007-07-31
US2398508P 2008-01-28 2008-01-28
PCT/US2008/009108 WO2009017701A2 (en) 2007-07-31 2008-07-28 Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment

Publications (1)

Publication Number Publication Date
BRPI0814874A2 true BRPI0814874A2 (pt) 2019-09-24

Family

ID=40305124

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814874A BRPI0814874A2 (pt) 2007-07-31 2008-07-28 combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer.

Country Status (17)

Country Link
US (1) US20100249030A1 (pt)
EP (1) EP2182986A2 (pt)
JP (1) JP2010535201A (pt)
KR (1) KR20100042287A (pt)
CN (1) CN101808666A (pt)
AR (1) AR068048A1 (pt)
AU (1) AU2008282885A1 (pt)
BR (1) BRPI0814874A2 (pt)
CA (1) CA2694218A1 (pt)
CL (1) CL2008002224A1 (pt)
CO (1) CO6331446A2 (pt)
EC (1) ECSP109918A (pt)
MX (1) MX2010001340A (pt)
PE (1) PE20090902A1 (pt)
RU (1) RU2010106878A (pt)
TW (1) TW200911241A (pt)
WO (1) WO2009017701A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009004791A (es) * 2006-10-31 2009-08-19 Schering Corp Derivados de anilinopiperazina t metodos de uso de los mismos.
JP5103604B2 (ja) * 2006-10-31 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド
WO2009097233A1 (en) * 2008-01-28 2009-08-06 Schering Corporation Imidazopyrazines as protein kinase inhibitors
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
WO2011025706A2 (en) * 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
US8435976B2 (en) * 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
NZ599597A (en) 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP5824040B2 (ja) 2010-06-01 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピラジン
JP2013545776A (ja) * 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
EA027418B1 (ru) 2011-06-27 2017-07-31 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ
CN103204824B (zh) * 2012-01-12 2015-04-08 清华大学深圳研究生院 2-氨基噻唑-4-酰胺类衍生物及其制备方法与应用
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
JP2015534990A (ja) * 2012-10-22 2015-12-07 イージェニックス インコーポレイテッド 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
BR112015016793B1 (pt) * 2013-01-15 2021-12-28 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
SG10201806849WA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
TWI664164B (zh) 2014-02-13 2019-07-01 美商英塞特控股公司 作為ｌｓｄ１抑制劑之環丙胺
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9321766B1 (en) 2014-10-06 2016-04-26 Allergan, Inc. Kinase inhibitors
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
US10221172B2 (en) 2015-01-13 2019-03-05 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
JP6995623B2 (ja) 2015-04-03 2022-01-14 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのヘテロ環式化合物
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI765860B (zh) 2015-08-12 2022-06-01 美商英塞特公司 Lsd1抑制劑之鹽
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
MX2018012901A (es) 2016-04-22 2019-06-06 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CA3104760C (en) * 2018-06-26 2023-09-26 Kpc Pharmaceuticals, Inc. Benzimidazole derivatives and use thereof as idh1 inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
WO2024088192A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
JP4799864B2 (ja) * 2002-09-23 2011-10-26 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
WO2005002571A1 (en) * 2003-07-03 2005-01-13 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
US20060281778A1 (en) * 2005-03-09 2006-12-14 Schering Corporation Compounds for inhibiting KSP Kinesin activity
US7608643B2 (en) * 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
CN101370811A (zh) * 2005-11-10 2009-02-18 先灵公司 作为蛋白激酶抑制剂的咪唑并吡嗪化合物

Also Published As

Publication number Publication date
TW200911241A (en) 2009-03-16
US20100249030A1 (en) 2010-09-30
WO2009017701A3 (en) 2009-05-07
AR068048A1 (es) 2009-11-04
KR20100042287A (ko) 2010-04-23
EP2182986A2 (en) 2010-05-12
AU2008282885A1 (en) 2009-02-05
CO6331446A2 (es) 2011-10-20
CA2694218A1 (en) 2009-02-05
RU2010106878A (ru) 2011-09-10
PE20090902A1 (es) 2009-07-25
JP2010535201A (ja) 2010-11-18
WO2009017701A2 (en) 2009-02-05
ECSP109918A (es) 2010-02-26
CN101808666A (zh) 2010-08-18
MX2010001340A (es) 2010-06-02
CL2008002224A1 (es) 2009-07-17

Similar Documents

Publication Publication Date Title
BRPI0814874A2 (pt) combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
BRPI0923171A2 (pt) Prevenção e tratamento da diarréia causada por rotavírus.
BRPI0911669A8 (pt) sistemas e métodos para o aperfeiçoamento da eficiência da disposição de orifício de catéter
TNSN08400A1 (en) Organic compounds and their uses
BRPI0814941A2 (pt) Composição de tratamentode semente, e, método de tratamento de semente.
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
BR112012004149A2 (pt) terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI0811893A2 (pt) Composição de borracha acrílica e borracha vulcanizada da mesma, e suas aplicações.
BRPI0811870A2 (pt) Tratamento e prevenção de influenza
BR112012000185A2 (pt) composição para o tratamento de hiperplasia benigna da próstata
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
PL3216457T3 (pl) Związki i sposoby zapobiegania lub leczenia restenozy
DK2147122T3 (da) Enzymatisk kræftbehandling
TNSN08496A1 (en) Aminothiazoles and their uses
SMT201400172B (it) Derivati di 1-eterodiene ed agente di controllo diorganismi pericolosi
GB2455585B (en) Capsicum seeds for the treatment of eczema and dermatitis
PL381862A1 (pl) Zastosowanie związków pirydyniowych i sposób leczenia
BRPI0820998A2 (pt) Estabilização oxidativa de esteróis e ésteres de esteróis.
CL2007003837A1 (es) Uso de compuestos derivados de isosorbide en la prevencion y/o tratamiento de un trastorno intestinal tal como inflamacion intestinal.
BRPI0917554A2 (pt) agente de tratamento ou agente de prevenção para oesteoartrite
WO2010037095A3 (en) Agents and methods for the treatment of cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.